IL6 and rheumatoid arthritis: By blocking JAK1/2/3 activity, these agents effectively suppress proinflammatory cytokine signaling (e.g., IL‐6, IFNγ), thereby reducing synovitis, joint damage, and systemic inflammation in conditions such as RA [540].